Highest-materiality recent filing
AngioDynamics reports FY2026 Q4 pro forma sales $86.6M (+8% YoY); Med Tech growth 16.7%
Q4 FY2026 pro forma net sales $86.6M (+8.0% YoY); Med Tech $41.8M (+16.7%), Med Device $44.8M (+1.1%).
Filed patent infringement lawsuit against Endovascular Engineering on April 23, 2026 in Delaware District Court.
AngioDynamics Q3 FY2026: Med Tech sales up 19%, raises full-year guidance
Net sales $78.4M (+8.9% pro forma); Med Tech $37.3M (+19%) driven by Auryon, thrombectomy, NanoKnife.
CEO James C. Clemmer to retire by Nov 30, 2026; retention awards for NEOs
Clemmer will step down as CEO upon successor appointment or Nov 30, 2026; may extend month-to-month; to serve as consultant for one year.
AngioDynamics CEO presents at J.P. Morgan conference; slide content not disclosed in filing
President & CEO Jim Clemmer presented at J.P. Morgan 44th Annual Healthcare Conference on Jan 14, 2026.
AngioDynamics Q2 beats; raises FY26 guidance; CEO Clemmer to retire; Med Tech growth +13%
Q2 net sales $79.4M (+8.8% YoY); Med Tech $35.7M (+13.0%); GAAP EPS -$0.15, adj. EPS $0.00.
AngioDynamics shareholders elect two Class I directors, ratify auditor, approve say-on-pay
James C. Clemmer and Michael E. Tarnoff, MD elected as Class I directors with ~29.6M and ~29.2M votes for.
AngioDynamics Q1 FY2026: Med Tech sales up 26.1%; raises full-year guidance
Net sales $75.7M (+12.2% YoY pro forma); GAAP loss $0.26/sh, adj loss $0.10/sh.
AngioDynamics Reports Strong Q4 and Full Year FY2025 Results; Med Tech Revenue Up 22%
Q4 pro forma net sales $80.2M, up 12.7% YoY; Med Tech sales grew 22% to $35.8M.
AngioDynamics enters $25M secured revolving credit facility with JPMorgan Chase
Secured $25 million revolving credit facility from JPMorgan Chase, maturing May 28, 2027.
AngioDynamics raises FY2025 guidance after Q3; Med Tech sales up 22% YoY
Pro forma Q3 net sales $72.0M (+9.2% YoY); Med Tech $31.3M (+22.2%) driven by Auryon, AngioVac, AlphaVac, NanoKnife.
AngioDynamics hosts virtual Cardiovascular Investor Event on April 2, 2025
Event presentation slides furnished as Exhibit 99.1, but no specific financial or operational updates disclosed in filing.
AngioDynamics CEO presents at J.P. Morgan conference; no material financial updates
James Clemmer, President & CEO, presented at J.P. Morgan 43rd Annual Healthcare Conference on Jan 16, 2025.
AngioDynamics Q2 pro forma sales up 9.2% to $73.0M; raises FY25 EBITDA guidance to $1-3M
Pro forma net sales $73.0M (+9.2% YoY); Med Tech $31.5M (+25%) led by AngioVac (+50.7%), Auryon (+21.8%), AlphaVac (+33.3%), NanoKnife disposables (+23.1%).
AngioDynamics hosts NanoKnife IRE Prostate event; no material financial data
Virtual investor event on NanoKnife IRE for prostate held January 8, 2025.
Elected three Class III directors: Burgess, Johnson, Licitra each with >24.8M votes for, 5.99M broker non-votes.
AngioDynamics Q1 FY2025 net sales $67.5M (+1.1% pro forma); GAAP EPS -$0.31, adj. EPS -$0.11
Med Tech segment sales $28.0M (+8.7% YoY) driven by Auryon at $13.7M (+24.9%) and AlphaVac at $2.2M (+21.1%).
AngioDynamics pro forma Q3 FY2024 net loss $187.8M on $159.5M goodwill impairment
Pro forma net loss for Feb 29, 2024 quarter was $187.8M vs $13.7M a year ago; includes $159.5M goodwill impairment.
AngioDynamics Q4 pro forma revenue $71.1M; FY2025 outlook $282-288M, share buyback $15M
Pro forma Q4 net sales $71.1M (+1.9% YoY); Med Tech +11.3% to $29.3M, Med Device -3.8% to $41.8M.
Reported net sales $75.2M; pro forma $66.0M (+8.0% YoY). GAAP net loss $190.4M ($4.73/sh) includes $159.5M goodwill impairment and $22.0M litigation settlement.
AngioDynamics settles patent litigation with BD; $7M upfront, $2.5M annual minimums
One-time payment of $7M to BD, with $3M due within 5 business days and remainder over 12 months.
AngioDynamics appoints new Audit and Governance chairs; director class rebalanced
Wesley Johnson appointed as new chair of the Audit Committee.
AngioDynamics director Dennis Meteny to retire Jan 31, 2024; board reduced to 8
Dennis Meteny to retire from Board and as chair of Audit Committee, effective Jan 31, 2024.
AngioDynamics cuts FY24 revenue guidance to $320-325M; Q2 revenue $79.1M, Auryon sales up 12.9%
FY24 revenue guidance lowered to $320M-$325M from $328M-$333M; adjusted EPS loss widens to ($0.35)-($0.42) from ($0.28)-($0.34).
AngioDynamics Q2 Revenue $79.1M, Per-Share Loss $0.72; Restructuring Manufacturing; SVP Resigns
Net sales $79.1M (up 2.7% pro-forma); GAAP net loss $29.0M or $0.72 per share; adjusted loss $0.05 per share
AngioDynamics shareholders approve amended equity plan and elect directors at annual meeting
All four board nominees elected with votes ranging from 23.6M to 25.9M for; avg 24.7M for, 1.9M withheld.
AngioDynamics Q1 FY2024 revenue $78.7M, pro-forma +5.7%; adj. loss $(0.12)/share
Net sales $78.7M (ex-Dialysis/BioSentry +5.7% YoY); Med Tech +13.3% on Auryon +25.7%, NanoKnife +34.5%.
Board adds Lorinda Burgess; director equity grants fully vested
Lorinda Burgess appointed as Class III director effective July 19, 2023, expanding board to nine members.
AngioDynamics Q4 net sales up 4.7% to $91.1M; GAAP loss $0.54/share
Med Tech segment grew 17.2% to $26.5M, driven by Auryon +22%, NanoKnife +28%, AlphaVac +87%.
AngioDynamics sells dialysis & biopsy product portfolio to Merit Medical for $100M cash
Closed June 8, 2023; proceeds used to repay ~$49.8M in debt under credit agreement, terminating it.
AngioDynamics sells dialysis product portfolio and BioSentry to Merit Medical for $100M cash
Deal includes DuraFlow, DuraMax, Evenmore, Schon XL, Trio-CT, Vaxel Plus catheters and BioSentry biopsy product.
AngioDynamics wins court ruling invalidating three Bard patents in Delaware litigation
District Court granted AngioDynamics' Renewed Judgment as a Matter of Law on June 1, 2023.
AngioDynamics management to present at Needham conference; no material news disclosed
CEO Jim Clemmer and CFO Stephen Trowbridge to present at 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023.
Q3 net sales $80.7M (+9.1% YoY); GAAP loss per share $0.24 vs $0.13 loss last year; adjusted loss per share $0.03.
AngioDynamics presents at Raymond James conference; no material new information in filing
CEO Jim Clemmer and CFO Stephen Trowbridge presented at Raymond James 44th Annual Institutional Investors Conference on March 6, 2023.
AngioDynamics SVP, General Counsel and Secretary Richard Rosenzweig resigns effective Feb 27, 2023
Richard C. Rosenzweig resigned as SVP, General Counsel and Secretary effective February 27, 2023.
AngioDynamics presents at J.P. Morgan Healthcare Conference; no specifics available
CEO Jim Clemmer and CFO Stephen Trowbridge presented at 41st Annual J.P. Morgan Healthcare Conference on Jan 12, 2023.
Net sales $85.4M, up 9.1% YoY; Med Tech +29.7% to $24.5M, Med Device +2.6% to $60.9M.
AngioDynamics guides Q2 cash ~$28-30M; results due Jan 5, 2023
Expected cash at Nov 30, 2022 (Q2 FY2023 end): $28-30 million.
AngioDynamics loses patent infringement jury verdict to Bard on port products
Jury verdict found AngioDynamics' implantable port products infringe certain Bard patents (Nov 22, 2022).
AngioDynamics shareholders approve amended equity plan and ESPP at annual meeting
Shareholders elected Meteny (33.3M for, 0.9M withheld) and Tarnoff (24.2M for, 10.0M withheld) as directors.
AngioDynamics Q1 sales up 5.9% to $81.5M, GAAP loss $0.33/sh, reaffirms FY2023 outlook
Net sales of $81.5M increased 5.9% YoY; GAAP net loss of $13.0M or $0.33 per share vs $0.18 loss a year ago.
AngioDynamics loses antitrust jury verdict against C.R. Bard in PICC market
Jury found Bard did not unlawfully restrain competition in U.S. PICC market following two-week trial in N.D.N.Y.
AngioDynamics enters $105M credit facility; repays existing debt
New $75M secured revolving credit facility maturing 2027, plus $30M term loan facility for Auryon laser manufacturing costs.
AngioDynamics CFO presents at Canaccord conference; no new material disclosures in truncated exhibit
Stephen Trowbridge, EVP & CFO, presented at Canaccord Genuity 42nd Annual Growth Conference on August 10, 2022.
AngioDynamics Q4 sales $87M (+13% YoY), GAAP EPS -$0.16; FY23 rev guide $342-348M
Q4 net sales $87.0M (+13.2% YoY); Med Tech sales up 40% to $22.6M.
Net sales $74.0M (+3.9% YoY); Med Tech +28.6% driven by Auryon ($7.3M) and thrombectomy; Med Device -2.8%.
AngioDynamics presents at Needham conference; no new financial guidance or material data
CEO James Clemmer and CFO Stephen Trowbridge presenting at 24th Annual Needham Virtual Growth Conference on Jan 10, 2022.
AngioDynamics Q2 revenue +7.6% to $78.3M; adj. loss per share $0.02; guidance cut on margin and EPS
Net sales $78.3M (+7.6% YoY); Med Tech +36.4% driven by atherectomy/thrombectomy.
AngioDynamics begins full market release of AlphaVac F22 thrombectomy system
AlphaVac F22 mechanical thrombectomy system, 510(k) cleared, moves from limited to full market release.
James Clemmer resigned from his position as a Class II director on the Board and was immediately re-appointed as a Class I director
Jan Stern Reed as the new chair of the Nominating, Compliance and Corporate Governance Committee
the Board appointed Wesley Johnson as the new chair of the Audit Committee
On January 16, 2024, Dennis Meteny announced his intention to retire and resign from his position as a member of the Board of Directors (the “Board”) of AngioDynamics, Inc. (“AngioDynamics” or the “Company”) and as a member of the Compensation Committee and chair of the Audit Committee, effective January 31, 2024.
On December 29, 2023, David D. Helsel, Senior Vice President of Global Operations and R&D, notified the Company of his intention to leave the Company, effective January 12, 2024, in order to pursue other opportunities.
On July 19, 2023, the board of directors (the “Board”) of AngioDynamics, Inc. (“AngioDynamics”) approved an increase in the size of the Board to a total of nine directors and appointed Lorinda Burgess as a Class III director of AngioDynamics, effective immediately.
Max materiality 0.90 · Median 0.62 · Most common event earnings